Long-term follow-up from the phase 1/2a PLX120-03 trial reported durable responses with plixorafenib (PLX8394/FORE8394) in BRAF-altered primary CNS tumors. In the prespecified efficacy subgroup for BRAF V600E and MAPK inhibitor–naïve disease (N=9), the objective response rate was 67%, with all responses partial. Across the broader prespecified cohorts, ORR was 80% in high-grade glioma and 50% in low-grade/glional tumors. Progression-free survival was 56% at 12 months and 33% at 24 months, with a median treatment duration of 13.8 months and reports of prolonged on-treatment benefit in some patients without evidence of cumulative adverse effects.